Journal of Clinical Nuclear Medicine Publishes Results of Tiziana’s Nasal Foralumab in Study Treating Moderate Alzheimer's Disease

Core Insights - Tiziana Life Sciences announced a study demonstrating that intranasal foralumab significantly reduced microglial activation in a 78-year-old patient with moderate Alzheimer's disease, indicating a potential new treatment avenue for neurological disorders [1][2][7] Company Overview - Tiziana Life Sciences is a biotechnology company focused on developing immunomodulation therapies, with its lead candidate being intranasal foralumab, a fully human anti-CD3 monoclonal antibody [1][12] - The company aims to provide alternative routes of immunotherapy, which may enhance efficacy and safety compared to traditional intravenous delivery methods [12] Study Findings - The study published in the Journal of Clinical Nuclear Medicine utilized advanced PET imaging to assess microglial activation before and after treatment, revealing a notable reduction in neuroinflammation following intranasal foralumab administration [2][5] - This case marks the first use of 18F-PBR06-PET in a patient with moderate Alzheimer's disease and the first report of an Alzheimer's patient treated with nasal-foralumab [2][8] Future Directions - Tiziana Life Sciences plans to initiate a phase-2a study of nasal-foralumab in mild Alzheimer's disease, addressing the unmet need for disease-modifying therapies in this area [8][10] - The company has previously reported similar effects of nasal-foralumab in reducing microglial activation in patients with non-active secondary progressive multiple sclerosis [8][10]